Repository logo
 

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7), an exploratory analysis of a randomised controlled trial

Published version
Peer-reviewed

Type

Article

Change log

Authors

Emary, Katherine RW 
Golubchik, Tanya 
Aley, Parvinder K 
Ariani, Cristina V 
Angus, Brian 

Abstract

A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the United Kingdom from November 2020. Here we report efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19, against this variant.

Description

Keywords

Journal Title

The Lancet

Conference Name

Journal ISSN

0140-6736

Volume Title

397

Publisher

Elsevier
Sponsorship
MRC (MC_PC_19027)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
COVID-19 Genomics UK is supported by funding from the Medical Research Council, part of UK Research and Innovation, the NIHR, and Genome Research, operating as the Wellcome Sanger Institute.